https://doi.org/10.55788/7a32cbd9
“At Sheba Medical Center, we developed a novel technique to target pain from pancreatic cancer, involving the administration of a very high dose of radiation, not to the tumour but to the celiac plexus (25 Gy * 1),” explained Dr Yaacov Lawrence (Sheba Medical Center, Israel). A pilot trial delivered encouraging response rates for this approach [1], instigating the current, international, phase 2 study. Dr Lawrence and co-investigators included 149 patients with retroperitoneal pain from pancreatic cancer or any other cancer involving the celiac blood vessels [2]. A previous publication reported that the primary endpoint, change in Brief Pain Inventory ‘average pain’, was met [3]. Dr Lawrence presented the HR-QoL results of the study.
The Functional Assessment of Cancer Therapy – General (FACT-G) was significantly improved from baseline to 3 and 6 weeks after therapy (mean score 57 vs 63 vs 67; P<0.05). A similar result was observed for the FACT-Hep questionnaire (mean score 96 vs 107 vs 113; P<0.05), the hepatobiliary cancer subscale (P<0.05), and the FACT-Hep trial outcome index (P<0.05). Data from FACT-G subscales demonstrated that improvements were made on the physical well-being subscale (P<0.05) and the emotional well-being subscale (P<0.05) but not on the social/family and functional well-being subscales.
These results warrant further investigation of this promising approach for the pancreatic cancer population, with a treatment showing improved HR-QoL.
- Hammer L, et al. Int J Radiat Oncol Biol Phys. 2022;113(3):588–593.
- Lawrence YR, et al. Celiac plexus radiosurgery for pain management in advanced cancer: An international phase II trial, health-related quality of life (HRQOL) outcomes. Abstract 662, ASCO-GI 2023, San Francisco, CA, USA, 19-21 January.
- Lawrence YR, et al. Int J Radiat Oncol Biol Phys. 2022;114(5):1060–1061.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Palliative radiation therapy improves hepatic pain in HCC and liver metastasis Next Article
First-line NALIRIFOX superior to standard treatment in mPDAC »
« Palliative radiation therapy improves hepatic pain in HCC and liver metastasis Next Article
First-line NALIRIFOX superior to standard treatment in mPDAC »
Table of Contents: ASCO GI 2023
Featured articles
Oesophageal and Gastric Cancer
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer
Regorafenib offers survival benefit for patients with pre-treated gastric cancer
Radiotherapy or not in locally advanced oesophageal or junctional cancer?
Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial
S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?
LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer
3-year follow-up data confirms benefits of nivolumab plus chemotherapy
Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer
Promising phase 2 results for HER-Vaxx in gastric cancer
Anal and Colorectal Cancer
IMbrave 151 missed primary endpoint in advanced BTC
Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC
Mutation-based selection to identify patients suitable for panitumumab treatment
Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT
ctDNA appears useful in monitoring patients with anal cancer undergoing CRT
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC
Does cell-free DNA influence MRD testing in post-operative colon cancer?
OPERA: surgery may be avoided with adequate therapy in rectal cancer
Can we improve total neoadjuvant therapy for rectal cancer?
Hepatobiliary Cancer
Palliative radiation therapy improves hepatic pain in HCC and liver metastasis
Improved survival following postoperative sorafenib plus TACE in HCC
Quality-of-life benefits for tislelizumab in uHCC
Stereotactic body radiation therapy beneficial for patients with locally advanced HCC
SWOG 1815, first-ever phase 3 trial in BTC, fails
Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC
Pancreatic Cancer
First-line NALIRIFOX superior to standard treatment in mPDAC
Novel approach delivers quality-of-life benefits for patients with pancreatic cancer
Related Articles
March 12, 2021
Borderline resectable pancreatic cancer: phase 2 results
March 21, 2022
Persisting disparities in pancreatic cancer care
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com